Cancer vaccines: a promising field starting to come of age?

20 April 2023

At present, cancer vaccines are available mainly as part of clinical trials but, with ambitious biotech companies starting to grab the attention of big pharma and other investors with deep pockets, the global market for these immunotherapies is set to expand rapidly.

Worth an estimated $9 billion in 2023, the global cancer vaccines market’s value is expected to jump to $24.22 billion by 2033 by registering a compound annual growth rate of 12% in this period, according to a report from Future Market Insights.

Unlike vaccines to protect us from disease, cancer treatment vaccines are for people who already have the disease. Taking these products to market has proven even more challenging than for other vaccines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK